Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15433975 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL9993716 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL10987950 | 0.88 | SLC22A1 (0.54) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL8105104 | 0.87 | SLC22A1 (0.53) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL10831225 | 0.86 | OPRM1 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL10830448 | 0.86 | SLC22A1 (0.52) | SLC6A4 | |
| SCHEMBL13720895 | 0.86 | SLC22A1 (0.52) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL11045998 | 0.85 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL8097325 | 0.84 | SLC22A1 (0.51) | SLC6A2SLC6A4HTR2C | |
| SCHEMBL8097321 | 0.84 | SLC22A1 (0.51) | SLC6A2SLC6A4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014009767-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 1-ARYL 2-AMINOMETHYL CYCLOPROPANE CARBOXYAMIDE (Z) DERIVATIVES, THEIR ISOMERS AND SALTS | MICRO LABS LIMITED (IN) | 2014-01-16 | — | — | WO | disclosed |
| WO-2011158249-A1 | PROCESS FOR PREPARATION OF MILNACIPRAN INTERMEDIATE AND ITS USE IN PREPARATION OF PURE MILNACIPRAN | GLENMARK GENERICS LIMITED (IN) | 2011-12-22 | — | — | WO | disclosed |
| US-20100274050-A1 | SOLID MILNACIPRAN AND PROCESS FOR THE PREPARATION OF THE SAME | GLENMARK GENERICS LIMITED (IN) | 2010-10-28 | — | — | US | disclosed |
| US-4478836-A | 1-Aryl 2-aminomethyl cyclopropane carboxyamide (Z) derivatives and their use as useful drugs in the treatment of disturbances of the central nervous system | PIERRE FABRE S.A. (FR) | 1984-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274050-A1 | SOLID MILNACIPRAN AND PROCESS FOR THE PREPARATION OF THE SAME | GCG, AREG, CTSG | SLC6A2 1122/4885SLC6A4 628/4885SLC6A3 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.